­CAPhO Conference 2026

This symposium aims to empower Canadian pharmacists with clinical insights and practical strategies to help to integrate and deliver PD-1 targeted immunotherapy for recurrent/metastatic Nasopharyngeal Carcinoma (NPC).

Learning objectives:
At the end of this symposium, participants will be able to:

1.  Understand the topline data to support the recent Health Canada approval of PD-1 targeted immunotherapy for recurrent/metastatic Nasopharyngeal Carcinoma (NPC)
2.  Describe how immunotherapy is integrated and delivered within the Canadian cancer care system, including pathways, access models, and multidisciplinary coordination
3.  Identify lessons of excellence and best practices from pharmacists collaborating within the cancer care system to optimize patient outcomes and treatment support
 

Click here for more details

This presentation explores the evolving therapeutic landscape of platinum-resistant ovarian cancer (PROC), with a focus on antibody–drug conjugates (ADCs) and targeted therapies. It will review mechanisms of action, indications, and emerging clinical data informing treatment selection. Emphasis will be placed on the pharmacist’s integral role within multidisciplinary care, including proactive patient-centered interventions, collaboration, communication, and advocacy for molecular testing and safety monitoring. Attendees will gain practical strategies for administering ADCs, monitoring and managing adverse events, and implementing effective workflows to optimize toxicity mitigation, patient education, and overall treatment outcomes in PROC within contemporary oncology practice.

 
Learning objectives:
At the end of this symposium, participants will be able to:

1. Describing the evolving landscape of PROC, including therapeutic mechanisms and indications for targeted therapies and ADCs;
2. Valuing the pharmacist’s role as an integral member of the multidisciplinary care team, including proactive patient-centered interventions, collaboration, communication, and advocacy for molecular testing and safety monitoring
3. Applying best practices in administering, monitoring, and managing adverse events associated with ADCs and targeted agents, as well as implementing effective multidisciplinary workflows for toxicity mitigation and patient education

Click here for more details

This 30 minute CAPhO video explores how exercise can be used as an effective and safe adjunct to treatment for cancer patients with bone metastasis. It highlights key evidence supporting exercise programs in cancer care, the role of exercise in prehabilitation and rehabilitation, and offers tips for safely prescribing exercise to patients with bone metastases. The session concludes with practical resources, aligning with CAPhO’s theme of innovative approaches to managing bone metastases.

Learning objectives:
At the end of this symposium, participants will be able to:

1. Understand the evidence supporting exercise programs in cancer patients
2. Learn the role of exercise in cancer prehabilitation and rehabilitation
3. Identify key priorities and considerations when prescribing exercise for patients with bone metastases
4. Explore professional resources available to support clinical practice

Click here for more details

Don’t miss the congress’ opening symposium! This highly interactive session unites leading oncologist and pharmacy experts to explore cutting edge strategies for optimizing subcutaneous (SC) checkpoint inhibitor (CPI) delivery. Mimicking the concept of a science fair, this memorable symposium will showcase pharmacy-led pilot initiatives that will uncover how SC CPI delivery can transform Canadian oncology practice—enhancing patient-centred care, streamlining workflows, and improving system efficiency.

Learning objectives:
At the end of this symposium, participants will be able to:

1. Explain the potential impact of SC CPI delivery on Canadian oncology practice, patient-centred care, and system efficiency.
2. Describe pharmacy-led pilot initiatives for SC CPI delivery, describing the opportunities, challenges, and expected outcomes of each project.
3. Identify actionable strategies and best practices to support the adoption, scaling, and sustainability of SC CPI delivery models in their own institutions.

Click here for more details

Additional fees apply. Click here for more information about the Workshop.

Additional fees apply. Click here for more information about the Workshop.

Additional fees apply. Click here for more information about the Workshop.

Precision oncology is changing how advanced HR+/HER2− breast cancer is managed — and oncology pharmacists are central to safe, effective delivery.

Experts will break down the clinical relevance of PIK3CA mutations, where targeted therapies fit in the treatment pathway, and what this means for your daily practice. Gain practical, pharmacist-focused strategies for patient counselling, monitoring, and preventing and managing treatment-related adverse events.

Come for a mocktail. Leave with concise, practice-ready tips you can use with patients the very next day

Learning objectives:
At the end of this symposium, participants will be able to:

1. Describe the role of PIK3CA mutations in the prognosis of breast cancer patients and the clinical impact of PIK3CA pathway-targeted therapies
2. Develop comprehensive strategies for patient education and counselling regarding PIK3CA targeted therapies and their place in the patient treatment journey
3. Summarize the approach to monitoring and managing common adverse events associated with PIK3CA-targeted therapies

Click here for more details

This presentation will explore the critical role of allied health professionals in the administration and patient care of Zolbetuximab for gastric and gastroesophageal junction (GEJ) cancers. Attendees will gain insights into the collaborative approach required for effective patient management, including the integration of multidisciplinary teams in treatment planning and delivery.

Learning objectives:
At the end of this symposium, participants will be able to:

1. Explore the critical role of allied health professionals in the administration and patient care of targeted therapies for G/GEJ cancers.
2. Gain insights into the collaborative approach of multidisciplinary teams in treatment planning and delivery.
3. Discuss the development of management plans to mitigate adverse events to improve patient care and outcomes.
4. Review an innovative tool to improve patient management with new targeted therapies.

Click here for more details

Join GSK for an interactive and dynamic panel discussion on optimizing care for RRMM patients treated with BCMA targeting ADCs. Experts will share practical tips on multidisciplinary team communication and managing eye related side effects, including using ophthalmic exams to guide dose adjustments.

Learning objectives:
At the end of this symposium, participants will be able to:

1.     Identify the distinct adverse event profile associated with antibody-drug conjugates (ADCs) used in multiple myeloma
2.    Describe the pharmacist’s role in patient counseling, particularly in helping patients manage ocular and other treatment-related effects.
3.    Apply coordinated patient care models to strengthen communication strategies and appropriately manage dosing changes and treatment holds as care team—including oncologists, eye care providers (ECPs), and pharmacists.
4.    Discuss practical approaches workflow management to optimize scheduling, ADC administration, and continuity of care.

Click here for more details

Join experts as they review current evidence and guidelines in early breast cancer, develop practical strategies to manage adverse events, drug interactions, and adherence, and explore real-world models demonstrating the impact of pharmacist-led care. Attendees will leave equipped with actionable insights to strengthen their role within multidisciplinary oncology teams and optimize patient outcomes.

Learning objectives:
At the end of this symposium, participants will be able to:

1. Identify patients appropriate for adjuvant CDK4/6 inhibitors based on recurrence risk and trial criteria.
2. Proactively manage CDK4/6 inhibitor–related toxicities, drug interactions, and dose modifications.
3. Apply pharmacist-driven interventions to support adherence and team-based care.

Click here for more details

Management of polycythemia vera (PV) continues to evolve as treatment goals expand beyond hematocrit control and symptom management toward long-term disease modification. This symposium will explore the evolving therapeutic landscape and emerging clinical evidence in PV, including findings from prospective studies of novel long-acting immunomodulatory therapies such as ropeginterferon alfa-2b.

Learning objectives:
At the end of this session, participants will be able to:

1. Describe the evolving treatment landscape for PV, including goals beyond symptom control.
2. Discuss clinical data supporting early intervention in low- and high-risk patients.
3. Recognize the potential role of novel interferon therapies in disease modification.
4. Compare safety and dosing characteristics of current treatment options.
5. Identify practical considerations for initiating therapy, monitoring response, and navigating access.

Click here for more details

This symposium will aim to empower Canadian pharmacists with clinical insights and practical strategies to help optimize patient care throughout the Multiple Myeloma treatment journey, across the NDMM patient spectrum and at first relapse and beyond.

Learning objectives:
At the end of this symposium, participants will be able to:

1. Tailor the use of anti-CD38 containing regimens across the spectrum of Newly Diagnosed Multiple Myeloma (NDMM) to optimize long-term outcomes
2. Identify strategies to strengthen the coordination of patient care between CAR-T and referral centers
3. Integrate real-world evidence related to bispecific antibody dosing and administration into outpatient practice protocols

Click here for more details

Hear about how optimized, pharmacist-led models of care improve oncology patient outcomes. Michael LeBlanc will discuss foundational hybrid care frameworks and patient-centered KPIs. Liam Berrigan will present an innovative case study on decentralizing specialist access to bridge rural care gaps. Scott Edwards will demonstrate operationalizing practical clinical tools to optimize supportive care. The session will conclude with a fireside chat on innovative approaches to the role of oncology pharmacists, with a focus on bone health and the expanding scope in supportive care practices, followed by a presentation from the 2026 HOPE Award winners, celebrating groundbreaking pharmacy excellence in Canada.

Learning objectives:
At the end of this symposium, participants will be able to:

1.  Review the clinical foundations required for the use of denosumab, including patient assessment and screening, maintaining calcium homeostasis, and vitamin D intake.
2.  Navigate through drugapp.ca, an innovative online tool for oncology pharmacists. This demonstration will show you how to use its features, including the corrected calcium calculator, to help pharmacists proactively screen patients and safely administer injectable oncology drugs in a community setting.
3.  Develop actionable strategies to implement best practices for denosumab use and champion a proactive bone health mindset.

Click here for more details

Understand the critical role of CQI in enhancing oncology drug libraries. Learn how to leverage data analytics to optimize oncology libraries and improve clinical practice. Discover best practices for implementing CQI and data-driven approaches in oncology. Gain insights from real-world case studies and learn from the experiences of others.

Learning objectives:
At the end of this symposium, participants will be able to:

1. Explore a collaborative framework for drug library development
2. Enhancing drug libraries through continuous quality improvement (CQI) in oncology
3. Share best practices for successful application of CQI and data-driven approaches in oncology

Click here for more details

• Review current evidence and clinical considerations in managing multiple myeloma across treatment settings
• Explore strategies to optimize patient experience and workflow efficiency in oncology care
• Discuss health system considerations for integrating innovative therapies into clinical practice
   

Learning objectives:
At the end of this symposium, participants will be able to:

1. Review current clinical evidence and considerations for managing multiple myeloma across treatment settings
2. Describe the principles and processes involved in subcutaneous administration in oncology care
3. Identify strategies to integrate subcutaneous administration into pharmacy workflows to optimize patient care and operational efficiency.

Click here for more details

Join us to explore how subcutaneous (SC) immunotherapy is transforming Canadian oncology pharmacy practice. We’ll dive into the latest evidence, practical strategies, and real-world insights. Don’t miss your chance to be part of the conversation!

Learning objectives:
At the end of this symposium, participants will be able to:

1. Review the key evidence on how SC administration of anti-cancer drugs can improve healthcare system efficiency and patient outcomes
2. Implement practical strategies for integrating SC anti-cancer therapies into clinical practice, including protocol development, shared decision-making, patient scheduling, and transitioning from IV to SC administration
3. Apply real-world evidence and patient perspectives on SC anti-cancer therapies to identify opportunities to enhance care in the Canada

Click here for more details

This presentation explores Generational Intelligence - the ability to understand, appreciate, and adapt to generational differences in the workplace. Participants will learn how to navigate the unique values, communication styles, and work expectations of Baby Boomers, Gen X, Millennials, and Gen Z. Through real-life examples and practical tools, the session highlights strategies to bridge gaps, reduce misunderstandings, and foster inclusive collaboration across all generations.

Learning Objectives
Within the session, participants will be able to:

• Identify at least three key traits that differentiate each generation in the workplace
• Describe two generational misunderstandings that commonly impact team performance and morale
• Practice applying a framework to adapt their communication style to better engage one other generation
• Commit to one actionable strategy they can implement to foster multigenerational collaboration
• Evaluate their own biases or assumptions toward at least one generation using a guided reflection tool

This presentation will review pivotal clinical trials that will change the treatment landscape in oncology and hematology.  Key clinical trials will be reviewed and a summary of key items for every oncology pharmacist to take away for use in their daily practice.

Learning Objectives
By the end of the presentation, participants will be able to:

• Identify pivotal clinical trials that will change the hematology-oncology landscape.
• Use key learnings from the presentation and apply to daily use.
• Recall the reasons why the trials presented are considered pivotal.

CAPhO members are invited to join CAPhO’s Annual General Meeting either in person or virtually. CAPhO will share an update on its 2025 to 2028 Strategic Plan and introduce you to the incoming Board of Directors. Join the meeting for a chance to win complimentary registration to CAPhO Conference 2027.

CAPhO members, log in as a member and visit CAPhO’s Community Centre to review the Agenda, last year’s AGM Minutes and  Committee Chair reports.

Submit your questions in advance using this link. You may also ask questions during the meeting.

Artificial intelligence (AI) is already reshaping cancer services—improving diagnostics, streamlining oncology pharmacy workflows, and enabling safer, more personalised systemic anti-cancer therapy (SACT). This session reviews practical AI use cases relevant to cancer pharmacists, including workflow optimisation, aseptic preparation technologies, AI-assisted prescription verification and risk stratification, and toxicity prediction. Using NHS and international examples plus the BOPA AI Specialist Advisory Group priorities, we’ll explore benefits, limitations, governance, and how pharmacists can lead safe, ethical adoption in real-world practice.

Objectives:

1. AI types and use-case mapping
   • By the end of the session, participants will be able to identify at least 4 AI types (e.g., rule-based, machine learning, deep learning, generative AI) and complete a mapping exercise that links at least 6 oncology-pharmacy use-case domains to one potential application in their own service, recorded on the session worksheet.
2. Governance and ethics
   • By the end of the session, participants will be able to list at least 4 governance/ethical requirements for implementing AI in oncology pharmacy and will write 2 feasible mitigation actions (aligned to their workplace) to address identified risks, documented on the session worksheet.
3. Engaging with BOPA AI CAG and Professional Networks to Influence AI Adoption
   • By the end of the session, participants will be able to describe 3 ways the BOPA AI CAG (and at least one other relevant group/network) can influence safe and effective AI adoption in oncology pharmacy, and will identify 1 specific opportunity to get involved (e.g., join a working group, contribute to consultation, participate in a survey/pilot) by writing a personal commitment action they will complete within 4 weeks of the session.

Cancer during pregnancy is a devastating situation for the patient. The dilemma is when and how to optimally treat the cancer while balancing the patient’s and the baby’s safety. This presentation will discuss the optimal use of chemotherapy and also newer therapies to treat the pregnant cancer patient. The treatment of breast cancer in a pregnant patient will be used as a model for applying treatment decision principles and best practice recommendations. Case presentations will consolidate the theory presented and the principles and recommendations on how best to manage these patients.

Learning Objectives:

• Define the consequences and outcomes of using chemotherapy during pregnancy
• Describe how to treat a pregnant cancer patient
• Apply recommendations on the use of newer therapies for treating pregnant cancer patients
• Practical applications of acquired knowledge using breast cancer as a treatment model

Advances in breast cancer research are reshaping diagnostic frameworks and influencing treatment strategies. This presentation explores emerging classifications in breast cancer, focusing on ER-low, HER2-low, and triple-negative breast cancer and their growing clinical relevance. It provides clarity on current approaches to receptor status assessment, interpretation of pathology reports, and the practical implications of these distinctions for therapy choice. The session offers insights to support evidence-based decision-making and facilitate the integration of evolving concepts into everyday clinical practice.

Learning Objectives:
By the end of the session, participants will be able to:

• Acquire a basic concept in assessing estrogen receptor (ER) status in ER-low breast cancer and human epidermal growth factor 2 (HER2) status in HER2-low breast cancer.
• Determine ER and HER2 statuses based on the pathology report.
• Acquire a basic understanding of triple-negative breast cancer (TNBC) and how it differs from ER-low and HER2-low breast cancer.
• Apply ER, HER2, and triple negative status to guide treatment selection in clinical practice.

This presentation inspires pharmacy technicians to recognize and embrace their leadership potential within everyday practice. It focuses on developing practical leadership skills, including effective communication, accountability, and problem solving, that enhance teamwork and patient care. The session emphasizes leading through influence and initiative, even without a formal title, by modeling professionalism and taking ownership of responsibilities. Attendees will be able to create a realistic action plan to implement leadership behaviors in their current roles. Additionally, it encourages evaluation of potential pathways to formal leadership positions and supports technicians in envisioning a future in pharmacy leadership. Technicians can and should, take confident and purposeful steps toward achieving their career goals.

Learning Objectives:

• Recognize the leadership potential within the pharmacy technician role
• Develop practical leadership skills through effective communication, accountability and problem solving
• Explore ways to lead without a formal title
• Create an action plan to apply leadership behaviors
• Identify formal leadership positions of interest
• Envision your future in pharmacy leadership and take confident, purposeful steps toward attaining it

This session will explore the fundamentals of CAR-T cell therapy, including how CAR-T cells are manufactured, named, and their mechanism of action. Attendees will review current indications for available products, compare CAR-T cell therapy with bispecific antibody therapy, and examine potential adverse effects along with management strategies. The presentation will also highlight key opportunities for pharmacist involvement throughout the patient’s CAR-T cell journey.

Learning Objectives: 
By the end of this session, participants should be able to:

• Understand how CAR-T cells are made and their mechanism of action
• Define current indications for CAR-T cell therapy in Canada
• Describe similarities and differences between CAR-T cell therapy and bispecific antibody therapy
• Identify possible adverse effects from CAR-T cell therapy and outline strategies for their management
• Demonstrate potential timepoints for pharmacist involvement during a patient’s CAR-T cell journey
   

This session will reveal that the oncology medication journey is increasingly being shifted from the hospital to the home. With this new care dynamic, technology can play a pivotal role in ensuring patients feel supported and confident in managing their medication regimen while also allowing the care team to make informed decisions and escalate care when appropriate. 

At the end of the session, participants will be able to:

• Describe the shifting medication needs of patients in oncology care
• Identify key attributes that impact adoption, value and long-term utilization of a technology platform
• Apply a structured framework to assess, iterate and improve the performance of an innovative initiative prior to scaling the offering more broadly

Treatment of prostate cancer has always required careful balancing of treatment benefits and harms. We will discuss risk stratification from landmark clinical trials to identify patients most likely to benefit from pharmacotherapy. From newly diagnosed local disease to metastatic cases, current therapy options will be reviewed including what is meant by treatment intensification and when it should be employed. 

Learning objectives:
After this session participants will: 

• Identify high risk features for clinically localized prostate carcinoma using NCCN guidelines and EMBARK trial eligibility criteria
• Discuss when addition of an Adrogen Receptor Pathway Inhibitor (ARPI) to Androgen Deprivation Therapy (ADT) may benefit a patient with  localized prostate cancer
• Describe doublet and triplet therapies for metastatic Castration Sensitive Prostate Cancer and how to choose between them
• Define progression to Castration Resistance

Dr. O’Rourke will describe the current system in Canada for conducting health technology assessments and price negotiation of cancer drugs. He will identify key challenges associated with the high cost of new cancer drugs and will present options for addressing the ethical and affordability challenges. Dr. O’Rourke will also identify major global trends that have the potential to impact the availability, access, and price of oncology drugs in Canada.

Learning Objectives:

• By the end of the session, participants will be able to describe the Canadian process for determining the value of new drugs including the process for price negotiation and listing by provincial and territorial governments.
• Following the session and with a subsequent review of the CDA-AMC and pCPA websites, participants will be able to understand and apply key components of the deliberative framework used by the pCODR Expert Review Committee to formulate their reimbursement recommendations.
• Following the session, participants will be able to identify and implement practical solutions that address the ethical and affordability challenges associated with high-cost cancer drugs.
• Upon conclusion of the session and with further self-reading, participants will have a greater understanding of global market access trends and challenges for oncology drugs and will be able to identify approaches to manage oncology drug access in Canada.

This session will highlight the latest treatment algorithms for ovarian, endometrial, and cervical cancers, showcase innovative pharmacist-led models of care, and share practical strategies to strengthen interprofessional collaboration. Walk away with actionable insights to elevate your impact on patient outcomes.

Learning Objectives

• Analyze the latest treatment algorithms for ovarian, endometrial, and cervical cancers — what’s new and what matters most for pharmacists.
• Evaluate innovative pharmacist-led models of care that are transforming gynecologic oncology practice.
• Apply practical strategies to integrate evidence-based pharmacist interventions into interprofessional cancer teams.

Yoga
Centennial Hall A, TCU Place

Running and Walking Groups
Meet in Hilton Lobby at 17:00

Visit the Networking Events page for more details.

Buses Depart from Hilton Lobby and Holiday Inn Lobby at 18:45, 19:00 and 19:15.

This interactive, case-based session examines the management of double-exposed CLL/SLL in patients who have progressed after BTK and BCL-2 inhibitor therapy. Through real-world scenarios, participants will explore current challenges, compare treatment strategies, and identify practical approaches to improving outcomes. The discussion will highlight clinically relevant differences in efficacy and toxicity, potential drug interactions, and evidence-based recommendations to support personalized care. Attendees will gain actionable insights to apply best practices and confidently navigate complex therapeutic decisions in a rapidly evolving treatment landscape.

Be part of the conversation as we explore the evolving treatment landscape and strategies to optimize patient outcomes in double-exposed CLL/SLL

Learning objectives:
At the end of this symposium, participants will be able to:

1. Understand the current unmet need and evolving clinical landscape in double exposed CLL/SLL by reviewing real-world data and assessing available treatment options.
2. Identify clinically significant differences in efficacy and toxicity across treatment options for double-exposed CLL/SLL and apply strategies to optimize therapeutic outcomes in clinical practice.
3. Integrate evidence-based treatment approaches into patient management plans to deliver personalized care and improve outcomes for double-exposed CLL/SLL

Click here for more details

This roundtable discussion will focus on considerations for leaders to create conditions for disclosure after medication errors to happen well, managing disclosure when multiple providers and patients are involved, disclosing uncertainty when harm is unclear, and potential gaps between policy and real-world decision-making.

Since the legalization of recreational cannabis in Canada in 2018, the use of cannabis in the general population has increased. This roundtable will provide an opportunity for interactive discussion pertaining to the use of cannabis after a cancer diagnosis. 
Potential topics for discussion include:
* current indications for cannabis use in cancer care
* types, strains, formulations, routes of administration of cannabis, including pharmacokinetic/dynamic considerations
* practical information for patients such as dosing, side effects, contraindications, and cautions

The discussion will center around antimicrobial prophylaxis for patients starting bispecific T-cell engager (BiTE) therapy, with an added focus on anti-BCMA targeting therapies.  Come share your experiences and learn about the practices of others across Canada!

This round‑table session introduces participants to Motivational Interviewing (MI) and Brief Action Planning (BAP), two evidence‑informed communication approaches that help uncover patient motivation and strengthen the quality of medication counseling conversations. Through quick demonstrations, practical case discussions, and hands‑on practice, you’ll gain practical skills that you can immediately bring into your patient conversations.

This discussion will include a review of vaccines indicated in adult cancer patients, when to administer them to maximize effectiveness, and minimize harm. As well as, where patients can receive vaccination and counselling on the important role they play in preventing illness.

Medication reconciliation has been shown to be an essential service that prevents medication errors and ensures medication safety in cancer patients during transitions of care.  We will discuss the current challenges that exist and share ideas for getting started.      

Participants will engage in a focused discussion on the emerging role of psychedelic-based treatments in palliative oncology—spanning research advances, real-world use, and interaction concerns. The session invites attendees to consider how these therapies may widen the therapeutic “sky” of supportive cancer care and what role oncology pharmacy can play.

The Town Hall is an opportunity for members of the oncology pharmacy community to ask questions, discuss issues, share ideas, get updates and learn more about CAPhO Association's initiatives. 

Submit your questions in advance using this link. You may also ask questions during the Town Hall.

• Administration: Jayde Richards – Mesna Utilization in Current Cancer Care Alberta Regimens versus Established Guidelines: A Cost-Minimization Analysis

• Pharmacy practice (non-research based): Amy Lim – Beyond Irritant, Not Quite Vesicant? Irritant with Vesicant Properties: An Updated Approach Extravasation Hazard Classification

• Research - Clinical: Erin Cho – Real-World Outcomes and Prescribing Patterns of Niraparib and Olaparib in Second-Line Maintenance Therapy for Relapsed Ovarian Cancer at BC Cancer 

• CAPhO Participant's Choice Award

This panel session explores the foundational principles of ethical decision-making in oncology, focusing on real-world dilemmas that challenge healthcare professionals. Through case-based discussions, panelists will examine how to navigate complex situations involving patient autonomy, informed consent, cultural considerations, and access to care. The session emphasizes the application of the four pillars of ethical care – beneficence, non-maleficence, autonomy and justice – in pharmacist practice.

Learning Objectives
By the end of the session, participants will be able to:

1. Discuss the key pillars of ethical discussions
2. Identify common ethical dilemmas in oncology health care

This presentation reviews cutaneous toxicities associated with immune checkpoint inhibitors, which occur in up to 50% of patients and reflect immune activation across multiple organ systems. It emphasizes early recognition, patient education, and preventative skincare using a simple “cleanse, moisturize, protect” approach. Common skin manifestations include pruritus, eczematous, lichenoid, psoriasiform, bullous, and exanthematous eruptions. Management is stepwise, prioritizing topical therapies and minimizing systemic steroids when possible due to potential negative oncologic outcomes. Emerging evidence supports targeted treatments such as biologics for refractory cases. Overall, the talk highlights practical, Canadian-aligned algorithms to optimize dermatologic care while preserving cancer treatment efficacy.  

By the end of the session participants will be able to:

1. Apply a standardized clinical algorithm to the initial assessment of patients with suspected treatment-related skin toxicity
2. Identify at least five of the most common cutaneous toxicities associated with immune checkpoint inhibitors
3. Select appropriate first-line +/- second-line management strategies for the common immune-related cutaneous adverse events

This symposium will examine the evolving management of follicular lymphoma across the disease continuum. Faculty will review disease biology, risk stratification, and frontline strategies. Emphasis will be placed on the rapidly changing relapsed/refractory landscape, treatment sequencing, patient selection, emerging therapies, and management of toxicities. Through case-based discussion, participants will gain practical, evidence-informed strategies to optimize patient selection, toxicity management and therapeutic decision-making in clinical oncology pharmacy practice. 

LEARNING OBJECTIVES:
By the end of this session, participants will be able to:

1. Describe the underlying biology and typical clinical presentation of follicular lymphoma (FL)
2. Discuss current treatment options and upcoming therapies, including evolving standards of care for FL with a focus on relapsed or refractory (R/R) FL
3. Apply best practices and real-world insights to optimize FL care in clinical pharmacy settings

Click here for more details (Eng)

Click here for more details (Fr)